New Publication: clinical data demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC
Photocure ASA, The Bladder Cancer Company, announces the publication of the study “The Impact of Blue Light Cystoscopy Use Among Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence”. The article was published online 28 April 2023 in the peer-reviewed medical journal Clinical Genitourinary Cancer.
In February 2023, clinical data from the Veterans Affairs (VA) BRAVO study was presented at the ASCO Genitourinary Cancers Symposium in San Francisco, USA. The data demonstrated a significant decrease in the risk of recurrence and prolonged time to recurrence following Blue Light cystoscopy (BLC®) with Cysview® compared to White Light cystoscopy (WLC) alone.
The study was conducted with support from Photocure and aims to describe bladder cancer outcomes and the impact of blue light cystoscopy (BLC®) with Cysview® among non-muscle invasive bladder cancer (NMIBC) patients in an equal access setting, i.e., the United States Veterans Affairs Healthcare System (VA). Patients diagnosed with NMIBC within the VA who received BLC were assessed to determine association between BLC and recurrence, progression, and overall survival; and further, whether these outcomes differed by race.
378 patients were included in the study. Median follow-up was 40.7 months from bladder cancer diagnosis. Median time to first recurrence following BLC was longer vs. WLC alone (40 (33-NE) vs. 26 (17-39) months). Recurrence risk was significantly lower following BLC (Hazard Ratio (HR) 0.70; 95% Confidence Interval (CI)). There was no significant difference in recurrence (HR 0.69; 95%CI), progression (HR 1.13; 95% CI), and overall survival (HR 0.74; 95% CI) following BLC by Black vs. White race, which suggests benefits of equal access to care. These findings will be further investigated in future studies.
Read the publication: https://www.clinical-genitourinary-cancer.com/article/S1558-7673(23)00098-8/fulltext